Skip to content
The US Labor Department released the September jobs report Friday morning at 8:30 a.m. ET....
ATLANTA, Oct. 2, 2020 /CNW/ -- The Home Depot®, the world's largest home improvement retailer, today announced that Edward "Ted" P....
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like......
If you want to know who really controls CrowdStrike Holdings, Inc. (NASDAQ:CRWD), then you'll have to look at the......
It’s been a thrilling year of ups and downs for Inovio (NASDAQ:INO). INO stock rocketed as much as 1,000% earlier this year following news that Inovio had a leading candidate in the race for a novel coronavirus vaccine. Things have gotten more complicated since summer, though.
Source: Ascannio / Shutterstock.com The government left Inovio out of its multi-billion dollar Operation Warp Speed to hurry along vaccine development. Inovio’s small trial size — compared to rivals — raised doubts about the quality of its research.
And repeated advances in other Covid-19 vaccine programs made it appear that Inovio was falling behind. Still, Inovio investors had hope. As recently as two weeks ago, INO stock popped 50% on a favorable corporate update.InvestorPlace - Stock Market News, Stock Advice & Trading Tips
On Monday, however, everything changed. The Food and Drug Administration (FDA) hit Inovio’s Covid-19 vaccine with a dreaded partial clinical hold. The 7 Top Robinhood...
What with all the trials under way to produce a vaccine for the novel coronavirus these days, trials of another kind have popped up, enough to make investors ill. Shares in Inovio Pharmaceuticals (NASDAQ:INO) cratered by a third in just 48 hours, beginning on Monday Sept. 28, after news that the FDA halted a planned Phase 2/3 clinical trial of its Covid-19 vaccine candidate INO-4800. Not long before that, AstraZeneca (NYSE:AZN) suspended a trial when a previously healthy 37-year-old woman was hospitalized on Sept. 5 after receiving her second dose of a vaccine in clinical trial. The question is whether maladies such as these might infect entrants such as iBio (NYSEAMERICAN:IBIO) and IBIO stock.
Source: Shutterstock Before you blurt out an answer, let’s take a second to appreciate just how complicated the vaccine milieu is at this point. Behold:
At least 15 companies are vying to cross the finish line first in the vaccine...
(Bloomberg) -- U.S. President Donald Trump said early Friday that he has tested positive for coronavirus along with his wife and one of his closest aides, throwing an already volatile campaign into deeper disarray just one month before the election.“Tonight, @FLOTUS and I tested positive for COVID-19. We will begin our quarantine and recovery process immediately. We will get through this TOGETHER!,” the president said on Twitter, hours after Bloomberg News reported that the adviser, Hope Hicks, had fallen ill with the virus.The election campaign against Democrat Joe Biden has focused heavily on Trump’s handling of the coronavirus, which has already killed more than 200,000 Americans and deepened inequalities. Biden and others have criticized Trump’s response as slow off the mark and ineffective.Biden was expected to be tested for the virus on Friday, according to a person familiar with his campaign’s plans. The two shared a stage Tuesday at the presidential...
